This is the title of a new paper published future oncology With co-authors Tara Graff, Sawreet Bains Chawla, Monica June, Nicole Heaps, Abulbishar Alsharif, David Tybor, Donald C. Moore, Nadine Zawadzki, and Katherine Spurrier. The gist is below:
Objective
To quantify the time and cost savings in US oncology practices from using a single specific antibody (bsAb) for both relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) compared with two separate single-indication therapies.
Materials and Methods
The study conducted a national survey of physicians (oncologists, pharmacists, nurses/physician assistants) treating non-Hodgkin lymphoma (NHL) patients in the US to measure the impact of operational efficiencies identified through formative qualitative interviews with oncology staff. Quantitative analysis estimated time-savings based on survey data, assuming one new prescription per patient per year and 12 (DLBCL) and 15 (FL) administration visits per patient per year. Time-savings were combined with employees’ pay rates to estimate cost-savings.
Result
Among n = 105 respondents, drivers of operational efficiency included onboarding, coordination of insurance and financial assistance, and medication preparation. For a hypothetical community practice treating 100 BSAB-eligible patients (61% DLBCL, 39% FL), the total time-savings in the first year of adoption was 3110 hours, resulting in a total monetized time-savings of $278,013. For a hypothetical academic practice, the monetized time-savings in the first year of adoption was $963,074.
conclusion
Using a single bSAB to treat R/R DLBCL and FL is anticipated to result in substantial time and cost savings for oncology practices.
You can read the full paper here.
